Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

Core Viewpoint - The company Tonghua Jinma (000766.SZ) has provided an update on its new drug development, specifically the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is primarily aimed at treating mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress being normal. The company will disclose significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]. Group 1 - The new drug Amber Dihydroaminoacridine Tablets is intended for the treatment of mild to moderate Alzheimer's disease [2]. - The drug has completed comprehensive review work and is now in the final review stage [2]. - The company assures that all progress related to the new drug is normal [2].

Core Viewpoint - Tonghua Jinma's stock price has shown volatility, with a recent increase of 2.14% but a year-to-date decline of 1.16%, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a growth of 4.35% [2]. - Cumulative cash dividends since the A-share listing amount to 210 million yuan, with no dividends paid in the last three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 3.20% to 38,200, while the average number of circulating shares per person increased by 3.31% to 25,266 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings indicating shifts in investor sentiment [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第十次临时会议通知于2025年12月30日以微信 和电子邮件形式送达全体董事。 2.2025年12月31日上午9时30分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、董事会会议审议情况 审议并通过《关于公司以自有资产抵押向银行申请贷款的议案》 公司与中国建设银行股份有限公司通化分行不存在关联关系，本次申请贷款不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组，根据《深圳证券交易所股票上市规则》和 《公司章程》等相关规定，本事项经公司董事会审议后，无须提交公司股东会审议。 表决结果：同意9票，反对0票，弃权0票。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 鉴于2025年公司向中 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 1.通化金马药业集团股份有限公司第十一届董事会2025年第十次临时会议通知 于2025年12月30日以微信和电子邮件形式送达全体董事。 2.2025 年 12 月 31 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 证券代码：000766 证券简称：通化金马 公告编号：2025-46 通化金马药业集团股份有限公司 第十一届董事会 2025 年第十次临时会议决议公告 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 审议并通过《关于公司以自有资产抵押向银行申请贷款的议案》 鉴于 2025 年公司向中国建设银行股份有限公司通化分行申请的贷款即将到期， 为满足公司生产经营和发展的需要，公司拟再次向中国建设银行股份有限公司通化 分行申请最高额不超过 12,000 万元的融资贷款，在该额度期限内可循环滚动使用。 | 抵押人 | 抵押物名 ...

Core Viewpoint - The company, Tonghua Golden Horse, has announced a resolution from its 11th Board of Directors meeting to apply for a loan from the bank using its own assets as collateral, indicating a strategic move to secure financing for operational needs [1] Group 1: Loan Application Details - The company plans to apply for a financing loan not exceeding 120 million yuan, which is intended to be used in a revolving manner within the specified period [1] - The loan application is in response to an upcoming maturity of a loan previously applied to the Bank of China, Tonghua Branch, in 2025 [1] Group 2: Collateral Information - The financing will be secured by part of the company's own land and properties, with a total book value of 194.9281 million yuan as of September 30, 2025 [1] - The collateral represents 4.24% of the company's most recent audited total assets, indicating a relatively low leverage ratio [1] Group 3: Voting Outcome - The resolution to approve the loan application received unanimous support, with 9 votes in favor, 0 against, and 0 abstentions [1]

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with an increase of 82.23% year-to-date, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a year-on-year increase of 4.35% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of December 22, the stock price was 28.61 yuan per share, with a market capitalization of 27.651 billion yuan. The stock experienced a trading volume of 334 million yuan and a turnover rate of 1.23% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on September 11, where it recorded a net buy of 142 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 shares held per shareholder, an increase of 3.31% [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings compared to the previous period [3].

正是由于琥珀八氢氨吖啶片让通化金马拥有了创新药概念，因此其相关进展情况也备受机构投资者关 注。 通化金马(000766)12月15日披露的投资者关系活动记录表显示，公司于近日接待了申万宏源证券和建信 基金的调研。 通化金马主要从事医药产品的研发、生产与销售，公司目前形成了本部、圣泰生物、永康制药和源首生 物等组成的业务单元集群。公司及子公司产品涵盖抗肿瘤、微生物、心脑血管、清热解毒、消化系统、 骨骼肌肉系统、妇科系统、神经系统等多个领域。 此前，通化金马曾于2024年8月29日晚公告，公司于近日收到国家药品监督管理局签发的琥珀八氢氨吖 啶片上市申请的《受理通知书》。琥珀八氢氨吖啶片是具备完全自主知识产权的小分子化学I.I类国家级 新药，用于治疗轻中度阿尔茨海默病，于2007年11月获得I期临床试验批件，2015年8月获得III期临床试 验批件，并于2017年8月至2023年9月完成Ⅲ期临床试验并揭盲。 通化金马在2025年半年报中介绍，目前公司正严格按照国家药品监督管理局药品审评中心有关法律、法 规及指导原则开展新药上市申请相关工作。 "当前，琥珀八氢氨吖啶片已经完成专业审评的各项工作，正在进行最终的综合审评 ...

通化金马药业集团股份有限公司 投资者关系活动记录表 | | 专业队伍，打造创新营销模式，保证公司在新药销售的主 | | --- | --- | | | 导性、可控性，充分平衡药品的利润空间和患者可及性， | | | 做好新药上市的定价工作；结合市场的广泛需求，制定精 | | | 准营销策略。同时，现有生产体系已做好充分准备，设计 | | | 产能可满足阿尔茨海默病患者的用药需求，确保新药获批 | | | 后能够快速投入市场，为广大患者提供新的优质治疗选 | | | 择。 | | 关于本次活动是否涉 | 否 | | 及应披露重大信息的 | | | 说明 | | | 活动过程中所使用的 | 无 | | 演示文稿、提供的文 | | | 档等附件（如有，可 | | | 作为附件） | | | 投资者关系活动类别 | √特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） 申万宏源证券：张静含、仰佳佳 | | | 建信基金：马牧青 | | | 上市公司： | | 活动参与人 ...

通化金马（000766.SZ）12月11日在投资者互动平台表示，我公司研制的化学1类新药琥珀八氢氨吖啶 片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信 息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：你好董秘 ，最近新药审核进度怎么样了？ ...